` CDIO (Cardio Diagnostics Holdings Inc) vs S&P 500 Comparison - Alpha Spread

CDIO
vs
S&P 500

Over the past 12 months, CDIO has underperformed S&P 500, delivering a return of -71% compared to the S&P 500's +13% growth.

Stocks Performance
CDIO vs S&P 500

Loading
CDIO
S&P 500
Add Stock

Performance Gap
CDIO vs S&P 500

Loading
CDIO
S&P 500
Difference
www.alphaspread.com

Performance By Year
CDIO vs S&P 500

Loading
CDIO
S&P 500
Add Stock

Competitors Performance
Cardio Diagnostics Holdings Inc vs Peers

S&P 500
CDIO
539112
SLB
BKR
AMMN
Add Stock

Cardio Diagnostics Holdings Inc
Glance View

Market Cap
7.5m USD
Industry
N/A

Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.

CDIO Intrinsic Value
0.05 USD
Overvaluation 99%
Intrinsic Value
Price
Back to Top